Therefore, the antibodies targeting the chemokine receptor CCR4 may possess dual or multiple mode of action in some cancer indications, such as targeting the CCR4+ tumor cells and modulation of immunosuppressive tumor microenvironment including infiltrating Treg cells. The gene discussed is CCR4; the disease is neoplasm.